Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid concentrations in rhesus monkeys
Department of Drug Metabolism, Merck Research Laboratories, West Point, PA 19486, USA. Biochemical pharmacology
(Impact Factor: 5.01).
05/2009; 78(6):642-7. DOI: 10.1016/j.bcp.2009.05.026
Brain penetration of drugs which are subject to P-glycoprotein (Pgp)-mediated efflux is attenuated, as manifested by the fact that the cerebrospinal fluid concentration (C(CSF)), a good surrogate of the unbound brain concentration (C(ub)), is lower than the unbound plasma concentration (C(up)) for Pgp substrates. In rodents, the attenuation magnitude of brain penetration by Pgp-mediated efflux has been estimated by correlating the ratio of CSF to plasma exposures (C(CSF)/C(p)) with the unbound fraction in plasma (f(u)) upon the incorporation of the in vivo or in vitro Pgp-mediated efflux ratios (ERs). In the present work, we investigated the impact of Pgp-mediated efflux on C(CSF) in monkeys. Following intravenous administration to cisterna magna ported rhesus monkeys, the CSF and plasma concentrations were determined for 25 compounds from three discovery programs. We also evaluated their f(u) in rhesus plasma and ER in human and African green monkey MDR-transfected LLC-PK1 cells. These compounds varied significantly in the f(u) (0.025-0.73), and 24 out of 25 are considered Pgp substrates based on their appreciable directional transport (ER>2). The C(CSF)/C(p) was significantly lower than the corresponding f(u) (>or=3-fold) for 16 compounds regardless of a significant correlation (R(2)=0.59, p=4 x 10(-5)) when the C(CSF)/C(p) was plotted against the f(u). When the f(u) was normalized to the ER (f(u)/ER) the correlation was improved (R(2)=0.75, p=8 x 10(-8)). More importantly, only one compound showed the C(CSF)/C(p) that exceeded 3-fold of the normalized f(u). The results suggest that the impact of Pgp-mediated efflux in monkeys, similar to the case in rodents, is reasonably reflected by the gradient between the free concentrations in plasma and in CSF. Therefore, f(u) and Pgp ER may serve as useful measurements in estimating in vivo C(CSF)/C(p) ratios in monkeys, and potentially in humans.
Available from: Antonello Caruso
- "For Mdr1a substrates, a correlation between C_CSF/C_p and fu_p/ER was shown, where ER is the drug in vitro efflux ratio obtained in the Mdr1a transport assay. Similar findings were reported by He et al.  and by Tang et al.  in mice and rhesus monkeys, respectively. This suggests that the in vivo CSF-to-unbound plasma partition coefficient (Kp,uu = C_CSF/Cu_p) is inversely proportional to the in vitro ER. "
[Show abstract] [Hide abstract]
ABSTRACT: The unbound drug concentration in brain parenchyma is considered to be the relevant driver for interaction with CNS biological targets. Drug levels in cerebrospinal fluid (C_CSF) are frequently used surrogates for the unbound concentrations in brain. For drugs actively transported across the blood-brain barrier (BBB), C_CSF differs from unbound plasma concentration (Cu_p) to an extent that is commonly unknown. In this study, the relationship between CSF-to-unbound plasma drug partitioning in rats and the mouse Pgp (Mdr1a) efflux ratio (ER) obtained from in vitro transcellular studies has been investigated for a set of 61 CNS compounds exhibiting substantial diversity in chemical structure and physico-chemical properties. In order to understand the in vitro-in vivo extrapolation of Pgp efflux, a mechanistic model was derived relating in vivo CNS distribution kinetics to in vitro active transport. The model was applied to predict C_CSF from Cu_p and ER data for 19 proprietary Roche CNS drug candidates. The calculated CSF concentrations were correlated with CNS pharmacodynamic responses observed in rodent models. The correlation between in vitro and in vivo potency for different pharmacological endpoints indicated that the predicted C_CSF is a valuable surrogate of the concentration at the target site. Overall, C_CSF proved superior description of PK/PD data than unbound plasma or total brain concentration for Mdr1a substrates. Predicted C_CSF can be used as a default approach to understand the PK/PD relationships in CNS efficacy models and can support the extrapolation of efficacious brain exposure for new drug candidates from rodent to man.
Biochemical pharmacology 02/2013; 85(11). DOI:10.1016/j.bcp.2013.02.021 · 5.01 Impact Factor
Available from: onlinelibrary.wiley.com
[Show abstract] [Hide abstract]
ABSTRACT: In the last 40 years, especially with the application of new neurochemical and molecular biological techniques, there has been explosive progress in understanding how certain ligands and drugs are transported across the blood-brain barrier and choroid plexus out of brain and CSF. In the CNS, there are several separate efflux transporters with very broad specificity that are responsible for much of the efflux transport. This review focuses on three such transporters: organic acid transporter-3, peptide transporter-2 and P-glycoprotein for which there is substantial new information including 'knockout' models in mice and, in one case, dogs. Moreover, the structural biology and transport mechanism of P-glycoprotein at 3.8 angstroms is described. The overall objective is to show how this new knowledge provides a more thorough understanding (e.g., of molecular mechanisms) of efflux transport and in several cases leads to clinically relevant information that allows better treatment of certain CNS disorders (e.g., meningitis and brain cancer).
Journal of Neurochemistry 10/2009; 112(1):13-23. DOI:10.1111/j.1471-4159.2009.06451.x · 4.28 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: In this chapter, theoretical basis and specific examples are presented to illustrate the utility of the animal models in assessing
and understanding the underlying mechanisms of DDIs. In vivo assessments in an appropriate animal model are considered key
to help verify in vivo relevance of in vitro studies and substantiate a basis for extrapolating in vitro human data to clinical
outcomes. From a pharmacokinetic standpoint, an important consideration for successful selection of the animal model is based
on broad similarities to humans in key physiological and biochemical parameters governing drug absorption, distribution, metabolism,
or excretion (ADME) process of interest for both the interacted and the interacting drugs. Also equally important are specific
in vitro and/or in vivo experiments demonstrating animal–human similarities, usually both qualitative and quantitative, in
the ADME property/process under investigation. Additional insights can also be gained with the use of knockout animals lacking
specific drug transporters or drug-metabolizing enzymes and/or transgenic animal models with humanized mouse lines expressing
specific drug transporters and/or metabolizing enzymes of interest.
Enzyme- and Transporter-Based Drug-Drug Interactions, 12/2009: pages 283-297;
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.